Parotid-sparing Radiotherapy for Head and Neck Cancer
Author Information
Author(s): Nutting Christopher M, Morden James P, Harrington Kevin J, Urbano Teresa Guerrero, Bhide Shreerang A, Clark Catharine, Miles Elizabeth A, Miah Aisha B, Newbold Kate, Tanay MaryAnne, Adab Fawzi, Jefferies Sarah J, Scrase Christopher, Yap Beng K, A'Hern Roger P, Sydenham Mark A, Emson Marie, Hall Emma
Primary Institution: Royal Marsden Hospitals NHS Foundation Trust
Hypothesis
Parotid-sparing IMRT reduces the incidence of severe xerostomia compared to conventional radiotherapy.
Conclusion
Parotid-sparing IMRT significantly reduces the incidence of xerostomia and improves quality of life in patients with head and neck cancer.
Supporting Evidence
- At 12 months, 74% of patients receiving conventional radiotherapy reported grade 2 or worse xerostomia compared to 38% in the IMRT group.
- At 24 months, 83% of patients in the conventional group reported xerostomia compared to 29% in the IMRT group.
- IMRT patients showed significant recovery of saliva secretion compared to conventional radiotherapy patients.
Takeaway
This study shows that a special type of radiation therapy can help people with head and neck cancer keep their saliva and feel better after treatment.
Methodology
A phase 3 randomised controlled trial comparing parotid-sparing IMRT with conventional radiotherapy in patients with head and neck cancer.
Potential Biases
Potential bias due to lack of masking and differences in treatment delivery.
Limitations
The study was not masked, which may introduce bias, and it was not powered to detect small differences in survival outcomes.
Participant Demographics
Patients with histologically confirmed pharyngeal squamous-cell carcinoma, aged 37.5 to 82.8 years, with a mix of genders.
Statistical Information
P-Value
p=0.0027
Confidence Interval
95% CI 56–87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website